1 July 2023 false Taxfiler 2024.4 13442273business:PrivateLimitedCompanyLtd2023-07-012024-06-30 134422732023-06-30 134422732023-07-012024-06-30 13442273business:AuditExemptWithAccountantsReport2023-07-012024-06-30 13442273business:FilletedAccounts2023-07-012024-06-30 134422732024-06-30 13442273business:Director12023-07-012024-06-30 13442273business:RegisteredOffice2023-07-012024-06-30 134422732023-06-30 13442273core:WithinOneYear2024-06-30 13442273core:WithinOneYear2023-06-30 13442273core:ShareCapitalcore:PreviouslyStatedAmount2024-06-30 13442273core:ShareCapitalcore:PreviouslyStatedAmount2023-06-30 13442273core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-06-30 13442273core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-06-30 13442273core:PreviouslyStatedAmount2024-06-30 13442273core:PreviouslyStatedAmount2023-06-30 13442273business:SmallEntities2023-07-012024-06-30 13442273countries:EnglandWales2023-07-012024-06-30 13442273core:ComputerEquipment2023-06-30 13442273core:ComputerEquipment2023-07-012024-06-30 13442273core:ComputerEquipment2024-06-30 134422732022-07-012023-06-30 iso4217:GBP xbrli:pure
Company Registration No. 13442273 (England and Wales)
Ran Pharmaceuticals Ltd Unaudited accounts for the year ended 30 June 2024
Ran Pharmaceuticals Ltd Unaudited accounts Contents
Page
- 2 -
Ran Pharmaceuticals Ltd Company Information for the year ended 30 June 2024
Director
Satpreet Singh Ran
Company Number
13442273 (England and Wales)
Registered Office
41 Olympic Way Greenford London UB6 8NJ England
Accountants
Proficient Accountants 85 Great Portland Street First Floor London W1W 7LT
- 3 -
Ran Pharmaceuticals Ltd Statement of financial position as at 30 June 2024
2024 
2023 
Notes
£ 
£ 
Fixed assets
Tangible assets
466 
- 
Investments
31,623 
31,623 
32,089 
31,623 
Current assets
Debtors
21,455 
8,246 
Cash at bank and in hand
36,427 
23,527 
57,882 
31,773 
Creditors: amounts falling due within one year
(31,796)
(15,188)
Net current assets
26,086 
16,585 
Net assets
58,175 
48,208 
Capital and reserves
Called up share capital
100 
100 
Profit and loss account
58,075 
48,108 
Shareholders' funds
58,175 
48,208 
For the year ending 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 29 July 2024 and were signed on its behalf by
Satpreet Singh Ran Director Company Registration No. 13442273
- 4 -
Ran Pharmaceuticals Ltd Notes to the Accounts for the year ended 30 June 2024
1
Statutory information
Ran Pharmaceuticals Ltd is a private company, limited by shares, registered in England and Wales, registration number 13442273. The registered office is 41 Olympic Way, Greenford, London, UB6 8NJ, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
4
Tangible fixed assets
Computer equipment 
£ 
Cost or valuation
At cost 
At 1 July 2023
- 
Additions
699 
At 30 June 2024
699 
Depreciation
Charge for the year
233 
At 30 June 2024
233 
Net book value
At 30 June 2024
466 
5
Investments
Other investments 
£ 
Valuation at 1 July 2023
31,623 
Valuation at 30 June 2024
31,623 
- 5 -
Ran Pharmaceuticals Ltd Notes to the Accounts for the year ended 30 June 2024
6
Debtors
2024 
2023 
£ 
£ 
Amounts falling due within one year
Trade debtors
21,455 
8,246 
7
Creditors: amounts falling due within one year
2024 
2023 
£ 
£ 
Taxes and social security
3,871 
11,783 
Loans from directors
25,525 
2,585 
Accruals
2,400 
820 
31,796 
15,188 
8
Average number of employees
During the year the average number of employees was 1 (2023: 1).
- 6 -